The Products That Sink LegitScript Applications: Peptides, hCG, and the Med-Spa Menu Problem

The peptide problem, precisely

Peptides aren't categorically banned: semaglutide and tirzepatide are peptides, and dozens of FDA-approved drugs are peptide-based. The problem is the specific set of experimental peptides sold online for human use without any approved-drug pathway. LegitScript's own guidance names the usual suspects: Melanotan 2 (tanning), ipamorelin (muscle growth and recovery), tesamorelin (weight loss), CJC-1295 (performance), BPC-157 (injury recovery and anti-aging), thymosin beta-4 / TB-500 (muscle and injury recovery), and the GHRP family.

It gets sharper: the FDA has declared several of these (BPC-157, CJC-1295, and Melanotan II among them) impermissible for compounding due to safety concerns. That means even a licensed compounding pharmacy with a physician's order isn't a lawful path for them. A telehealth menu offering 'BPC-157 recovery protocols' isn't a disclosure problem; it's a catalog problem.

And the reach extends past your own site: LegitScript's application checklists list affiliations with sellers of unapproved drugs (impermissible peptides and bulk substances specifically) as a common certification barrier. If your platform, your pharmacy partner, or a co-owned brand sells them, your application inherits the problem.

Rule of thumb from the primary sources: if a peptide has no FDA-approved drug pathway and shows up in bodybuilding, tanning, or 'recovery stack' marketing, assume it's a certification barrier, on your site or your affiliates'.

“Research use only” makes you look worse

The most counterintuitive finding in LegitScript's peptide guidance: merchants who prominently label products 'not for human consumption' or 'for research use only' are more likely, in LegitScript's experience, to be engaged in unapproved peptide sales. The disclaimer reads as an attempted legal shield, not a safeguard.

What actually distinguishes a legitimate research-chemical supplier: real safeguards against personal-use sales: verifying buyers are professional researchers, quote-based ordering instead of an open cart, institutional billing. A storefront with a Buy Now button, consumer pricing, and an RUO disclaimer is the exact profile the payments industry is trained to flag.

For telehealth operators the lesson is simpler: never let RUO-labeled products share a brand, a domain, or a corporate family with your prescription business. The association costs more than the SKUs earn.

The med-spa menu traps

LegitScript's med-spa checklist names the offerings that most often block that category's certifications: steroids for bodybuilding purposes, hCG for weight loss, stem-cell and exosome therapy, and ozone therapy. If any of these are on the menu (or on a co-owned brand's menu), expect them to dominate the review.

A second tier gets extra advertising scrutiny rather than outright blockage: NAD+ claims, hyperbaric oxygen therapy, and hormone-replacement marketing that promises increased muscle mass. These survive certification when the claims stay within FDA/FTC substantiation rules, which in practice means wellness framing without disease-treatment or performance promises the evidence can't carry.

Two operational med-spa questions also recur: standing orders (be ready to show they're lawful in each state you use them) and IV infusion or vitamin-therapy programs (name every pharmacy that compounds or supplies them). Both are answerable, but only if you've done the homework before the analyst asks.

The gray zone: compounded GLP-1s and 'in-demand' peptides

LegitScript's guidance singles out semaglutide and tirzepatide for special scrutiny: legitimate approved products exist, popular demand is enormous, and illegal sellers cluster around both facts. Post-shortage, compounded versions need a documented patient-specific clinical rationale (we cover that fully in the compounded-GLP-1 guide), and any site offering them should expect its sourcing, prescribing model, and claims to be read closely.

The practical sort: approved-pathway products prescribed through a real clinical model are certifiable; experimental peptides marketed for human use are not; and compounded versions of approved drugs live in between, certifiable exactly to the extent the clinical-need documentation is real.

How to audit your own catalog

Walk your Rx menu, your wellness menu, and your affiliates' menus, and sort every item into three buckets: approved pathway (an FDA-approved product or a defensible compounded formulation with documented clinical need), scrutiny tier (NAD+, HBOT, HRT; keep the claims modest), and barrier tier (the named peptides, hCG-for-weight-loss, stem cell/exosome, ozone, anything RUO-labeled). The barrier tier doesn't get better copy; it gets removed, or it blocks the application.

Our free Preflight scanner runs the product-lexicon pass automatically: it flags the named peptides, the barrier-tier offerings, and RUO language on any page it can crawl, alongside the claims and disclosure checks. It won't judge your clinical documentation (nothing automated honestly can), but it will tell you in a minute whether your public catalog has a barrier-tier problem.

Certification reviews are catalog-first: reviewers can waive a copy problem during review, but they can't waive what you sell. Sort the menu before you spend the $975.